Urology Private Equity – Market Update

In recent years urology has grown as an attractive specialty target for private equity investors. With a historically fragmented landscape, large PE-backed platforms have increased their efforts to form partnerships in the last three years, making for a highly competitive M&A market. Private equity sponsors find the specialty to be an attractive space due to the size of the market & attractive demographics, opportunities for ancillary service growth and a continuous increase in demand for quality care. Investors looks to overcome the headwinds that private practices now face. These include administrative burdens that affect clinical capacity, staff and physician recruiting, and high capital expenditures for ancillaries such as pathology laboratories, lithotripsy equipment and ambulatory surgery center buildouts. According to the AUA’s 2021 Census, 52% of practicing urologists work in private practice, down from nearly 60% in 2017. As urology consolidation continues, the window to gain a first mover advantage will shrink. However, private equity remains an attractive option for groups seeking partnerships to achieve their clinical goals and succession plans.

Select Recent Private Equity Transactions in Urology

About Our Firm

Physician Growth Partners (PGP) is a transaction advisory firm that represents independent physician groups working with private equity.

We are differentiated healthcare transaction advisors providing:

• Senior partner involvement at every stage of the process

• Extensive physician practice transaction experience

• Unmatched relationships with all key private equity and strategic buyers interested in Urology

• Educational approach focused on partnership and cultural fit, while simultaneously achieving a market clearing valuation